Aurora Cannabis

ACB

Market cap $208M

NASDAQ | TSX: ACB From global leadership to local impact, Aurora continues to support Veteran-focused programs across Canada, addressing food security, mental health, and community engagement EDMONTON, AB, June 2, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, shares recent contributions through its Strains for Heroes program, expanding support for Veteran communities across Canada. Aurora's ongoing commitment to support Veterans includes five per cent of net profits from the sale of Strains for Heroes products being donated annually to veteran-focused organizations, up to a maximum of C$200,000.

NASDAQ | TSX: ACB EDMONTON, AB, May 28, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2026 on Thursday, June 11, 2026 at 8:00 a.m. Eastern Time | 6:00 a.m.

Many marijuana stock investors have a strong positive outlook on the future of the market. If you've been watching the cannabis sector, then you know how volatile and uncertain trading can be. Yet there have been changes that give more upside to what the future of investing can hold. As cannabis is now a class 3 substance federally, more companies are making shifts in their business to get in line with this new legislation.

NASDAQ | TSX: ACB Canadian grant protects Aurora‑developed genetics bred through the company's advanced research and breeding program EDMONTON, AB, May 14, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announced today it has been granted Plant Breeders' Rights in Canada for two proprietary cannabis cultivars developed through its world-class breeding program. This certification gives Aurora the exclusive rights to grow, propagate, and sell finished products produced from these varieties.

The cannabis sector continues to attract investors seeking growth opportunities in 2026. Marijuana penny stocks remain volatile. However, they also offer strong upside potential when market momentum improves. Many cannabis companies are now focusing on profitability, stronger balance sheets, and international growth opportunities. Because of this, traders continue monitoring the sector closely for breakout setups.

NASDAQ | TSX: ACB Q1 launches reinforce Aurora's medical‑first strategy, expanding access to high‑quality products across multiple formats Scaled launches across Canada, Europe and Australia support growing demand in regulated international medical markets Continued focus on quality, patient needs and reliable global supply through Aurora's extensive GMP‑certified network EDMONTON, AB, April 28, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian‑based leading global medical cannabis company, is significantly expanding its global medical cannabis portfolio, with new product launches rolling out across Canada, Europe and Australia. The company continues to shape the global cannabis landscape by introducing new products and formats around the world.

Aurora Cannabis Inc. has transformed into a cannabis-focused company with improving international revenue and margins, while spinning off its Bevo division. ACB's balance sheet now shows net cash of C$46.7 million, achieved through equity sales, and enterprise value trades at just 3.8x projected FY27 adjusted EBITDA. I target a 64% upside for ACB to US$5.58 within a year, based on a 6x FY28 adjusted EBITDA multiple, with the stock trading below tangible book value.

Trulieve founder and CEO Kim Rivers discusses the impact of Trump's administration reclassifying state-licensed medical cannabis from Schedule 1 to Schedule 3 on 'Varney & Co.' 00:00 Introduction & Reclassification Impact 02:19 Tax Reform & Business Normalization 03:18 Edibles vs. Vapes for Medical Use

The Trump administration reclassified medical marijuana as a less dangerous drug on Thursday. FDA-approved and state-licensed medical marijuana was rescheduled from a Schedule I drug to the less strict Schedule III category.

Marijuana stocks sold off Thursday, after acting U.S. Attorney General Todd Blanche signed an order rescheduling Food and Drug Administration-approved and state-licensed medical cannabis products as a less harmful substance — a move that led to celebration but also confusion among industry observers.